Materno-fetal Transfer of Anti-HCMV-IgG, Materno-fetal Transfer of Anti-VZV-IgG
Conditions
Keywords
Human Cytomegalovirus, Varicella Zoster Virus, Materno-fetal antibody transfer, Pregnancy, Gestational age
Brief summary
The aim of the study is to determine the total concentration of HCMV- and VZV-specific IgG-antibodies and the total concentration of neutralizing antibodies against HCMV in neonatal bloodstream depending on gestational age at birth.
Detailed description
For data gathering the investigators measure the main concentration of specific HCMV-/VZV-IgG-antibodies and the concentration of neutralizing IgG-antibodies against HCMV and VZV in maternal blood and in fetal bloodstream. Then the investigators compare the data of mother and newborn. Therefore, the investigators use the following blood samples: Mother: Venous blood sample taken at birth (+/- three days) Newborn: Blood sample of umbilical cord (= fetal bloodstream) taken immediately after birth. The investigators assign the data of each newborn (gestational age at birth) to the data of their respective mother for statistical evaluation. After finishing the study the investigators will destroy all residual blood.
Interventions
OTHERBlood samples
Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.
Sponsors
Johann Wolfgang Goethe University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
1 Minutes to 10 Minutes
Healthy volunteers
Yes
Inclusion criteria
* HCMV and/or VZV-seropositive pregnant woman who signed written informed consent form.
Exclusion criteria
* Newborns of underage mothers. * Newborns whose mother did not sign the written informed consent. * Pregnant women with a known hereditary or acquired immune deficiency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To measure the concentration of specific HCMV-/VZV-IgG-antibodies in fetal bloodstream depending on gestational age at birth. | Newborn: immediately after birth; Mother +/- 3 days at birth | Measurement of HCMV and VZV-antibodies in the fetal and the maternal circulation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Gauging the concentration of neutralizing IgG-antibodies against HCMV and VZV in fetal bloodstream depending on gestational age at birth. | Newborn: immediately after birth; Mother +/- 3 days at birth | Measurement of neutralizing IgG-HCMV and VZV-antibodies in the fetal and the maternal circulation |
Countries
Germany
Contacts
Primary ContactHorst Buxmann, PI
Backup ContactClara A Lüdeke, SI
Outcome results
None listed